Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
825 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02929576 | Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer(ENDEAR) | withdrawn | Phase 3 | 0 | PfizerINDUSTRY | 1 | Oct 22, 2018 | clinicaltrials |
| NCT00997360 | Study of PKI-179 Administered Orally to Subjects With Solid Tumors | withdrawn | Phase 1 | 0 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 0 |
| Sep 27, 2018 |
| clinicaltrials |
| NCT00375674 | A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer(S-TRAC) | completed | Phase 3 | 674 | PfizerINDUSTRY | 22 | Sep 21, 2018 | clinicaltrials |
| NCT02836028 | A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer | withdrawn | Phase 2 | 0 | PfizerINDUSTRY | 0 | Sep 18, 2018 | clinicaltrials |
| NCT00299494 | Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL) | completed | Phase 1 / Phase 2 | 119 | PfizerINDUSTRY | 13 | Mar 8, 2018 | clinicaltrials |
| NCT02122146 | A Study Of PF-06664178 In Patients With Advanced Solid Tumors | terminated | Phase 1 | 31 | PfizerINDUSTRY | 1 | Feb 19, 2018 | clinicaltrials |
| NCT00562965 | Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL) | terminated | Phase 3 | 29 | PfizerINDUSTRY | 14 | Jan 9, 2018 | clinicaltrials |
| NCT00867087 | Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 64 | PfizerINDUSTRY | 6 | Dec 5, 2017 | clinicaltrials |
| NCT01154140 | A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung(PROFILE 1014) | completed | Phase 3 | 343 | PfizerINDUSTRY | 31 | Nov 6, 2017 | clinicaltrials |
| NCT00868608 | Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma | completed | Phase 2 | 81 | PfizerINDUSTRY | 9 | Oct 31, 2017 | clinicaltrials |
| NCT01399840 | Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies | completed | Phase 1 | 33 | PfizerINDUSTRY | 2 | Sep 15, 2017 | clinicaltrials |
| NCT03184168 | Single-dose Study of [14C]Lorlatinib (PF-06463922) Metabolism In Healthy Male Volunteers | completed | Phase 1 | 6 | PfizerINDUSTRY | 1 | Sep 12, 2017 | clinicaltrials |
| NCT00728468 | A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients | completed | Phase 1 | 16 | PfizerINDUSTRY | 1 | Aug 2, 2017 | clinicaltrials |
| NCT00261846 | Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias | completed | Phase 2 | 571 | PfizerINDUSTRY | 27 | Jul 27, 2017 | clinicaltrials |
| NCT02824094 | Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC | no longer available | — | — | PfizerINDUSTRY | 1 | Jul 21, 2017 | clinicaltrials |
| NCT01858389 | A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 41 | PfizerINDUSTRY | 2 | Jul 18, 2017 | clinicaltrials |
| NCT01163253 | A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis | terminated | Phase 3 | 2,867 | PfizerINDUSTRY | 36 | Jun 26, 2017 | clinicaltrials |
| NCT00835978 | Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer | completed | Phase 2 | 213 | PfizerINDUSTRY | 6 | May 30, 2017 | clinicaltrials |
| NCT01360554 | ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer(ARCHER 1009) | completed | Phase 3 | 878 | PfizerINDUSTRY | 23 | May 24, 2017 | clinicaltrials |
| NCT01363297 | Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia | completed | Phase 2 | 72 | PfizerINDUSTRY | 1 | Apr 13, 2017 | clinicaltrials |
| NCT01268163 | The Pharmacokinetics and Safety Characteristics of Docetaxel in Patients With Cancer | completed | Phase 1 | 32 | Hospira, now a wholly owned subsidiary of PfizerINDUSTRY | 2 | Mar 20, 2017 | clinicaltrials |
| NCT01626547 | Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology | completed | — | 291 | Hospira, now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Mar 20, 2017 | clinicaltrials |
| NCT00444795 | Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene | completed | — | 520 | PfizerINDUSTRY | 1 | Feb 1, 2017 | clinicaltrials |
| NCT02201524 | Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis | terminated | Phase 2 | 59 | PfizerINDUSTRY | 2 | Oct 5, 2016 | clinicaltrials |
| NCT01937715 | A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer | terminated | Phase 1 / Phase 2 | 18 | PfizerINDUSTRY | 3 | Aug 18, 2016 | clinicaltrials |
| NCT00811070 | Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias | completed | Phase 2 | 63 | PfizerINDUSTRY | 1 | Jun 28, 2016 | clinicaltrials |
| NCT00631371 | Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects(INTORACT) | completed | Phase 3 | 791 | PfizerINDUSTRY | 30 | Apr 27, 2016 | clinicaltrials |
| NCT01367457 | INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus | completed | — | 243 | PfizerINDUSTRY | 1 | Apr 27, 2016 | clinicaltrials |
| NCT00141297 | A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer | completed | Phase 1 | 74 | PfizerINDUSTRY | 1 | Jan 5, 2016 | clinicaltrials |
| NCT00717925 | Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL) | completed | Phase 1 | 13 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 0 | Dec 9, 2015 | clinicaltrials |
| NCT01831466 | Tofacitinib Ointment For Chronic Plaque Psoriasis | completed | Phase 2 | 476 | PfizerINDUSTRY | 4 | Nov 25, 2015 | clinicaltrials |
| NCT00793871 | Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor(GIST) | completed | Phase 4 | 60 | PfizerINDUSTRY | 1 | Nov 20, 2015 | clinicaltrials |
| NCT00982657 | A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma | terminated | Phase 2 | 34 | PfizerINDUSTRY | 1 | Nov 20, 2015 | clinicaltrials |
| NCT01004822 | A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors | terminated | Phase 1 | 31 | PfizerINDUSTRY | 1 | Nov 20, 2015 | clinicaltrials |
| NCT00036270 | Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane(TEAM) | completed | Phase 3 | 9,779 | PfizerINDUSTRY | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00372996 | Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer | terminated | Phase 2 | 219 | PfizerINDUSTRY | 9 | Oct 28, 2015 | clinicaltrials |
| NCT00560235 | Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors | completed | Phase 1 / Phase 2 | 138 | PfizerINDUSTRY | 11 | Oct 28, 2015 | clinicaltrials |
| NCT00768755 | Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 180 | PfizerINDUSTRY | 11 | Oct 28, 2015 | clinicaltrials |
| NCT00932126 | This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors | terminated | Phase 1 | 35 | PfizerINDUSTRY | 2 | Oct 28, 2015 | clinicaltrials |
| NCT00965731 | Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer | completed | Phase 1 | 27 | PfizerINDUSTRY | 1 | Oct 28, 2015 | clinicaltrials |
| NCT01121575 | A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer | completed | Phase 1 | 70 | PfizerINDUSTRY | 2 | Oct 28, 2015 | clinicaltrials |
| NCT01337050 | Asian Phase I Study Of PF-03446962 | completed | Phase 1 | 36 | PfizerINDUSTRY | 2 | Oct 28, 2015 | clinicaltrials |
| NCT00557856 | A First In Patient, Study Of Investigational Drug PF-03446962 In Patients With Advanced Solid Tumors | completed | Phase 1 | 70 | PfizerINDUSTRY | 3 | Oct 19, 2015 | clinicaltrials |
| NCT01047358 | Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer | completed | — | 206 | PfizerINDUSTRY | 1 | Oct 8, 2015 | clinicaltrials |
| NCT02462707 | A Study Of PF-03084014 In Japanese Patients With Advanced Solid Tumors | withdrawn | Phase 1 | 0 | PfizerINDUSTRY | 0 | Oct 7, 2015 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials